Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma

Exploring EZH2-Proteasome Dual-Targeting Drug Discovery through a Computational Strategy to Fight Multiple Myeloma

Multiple myeloma is an incurable plasma cell neoplastic disease representing about 10–15% of all haematological malignancies diagnosed in developed countries. Proteasome is a key player in multiple myeloma and proteasome inhibitors are the current first-line of treatment. However, these are associat...

Full description

Bibliographic Details
Main Authors: Filipe G. A. Estrada, Silvia Miccoli, Natália Aniceto, Alfonso T. García-Sosa, Rita C. Guedes
Format: Article
Language:English
Published: MDPI AG 2021-09-01
Series:Molecules
Subjects:
multiple myeloma
polypharmacology
multitargeting (advantages)
EZH2
Proteasome 20S
molecular docking
Online Access:https://www.mdpi.com/1420-3049/26/18/5574

Similar Items

Similar Items